Introduction {#tca13039-sec-0001}
============

EGFR‐tyrosine kinase inhibitors (TKIs) have contributed significantly to improving the prognosis of patients with advanced non‐small cell lung cancer (NSCLC) harboring *EGFR* mutations. However, drug‐induced interstitial lung disease (ILD) has been recognized as a serious potential side effect. Recently, Ahn *et al.* reported that the combination of osimertinib, a third‐generation EGFR‐TKI, and durvalumab, an anti‐PD‐L1 immune checkpoint inhibitor (ICI), is not appropriate for patients with advanced *EGFR* mutation‐positive NSCLC, because of the increased incidence of ILD.[1](#tca13039-bib-0001){ref-type="ref"} Although 34 patients were treated with this combination therapy in their study, ILD was observed in 38% of all patients and 60% of Japanese patients.[1](#tca13039-bib-0001){ref-type="ref"} Moreover, recent reports also have described an increased incidence of ILD in patients administered osimertinib immediately after nivolumab, an anti‐PD‐1 antibody.[2](#tca13039-bib-0002){ref-type="ref"}, [3](#tca13039-bib-0003){ref-type="ref"}, [4](#tca13039-bib-0004){ref-type="ref"} It remains unknown whether the use of gefitinib or erlotinib, which are first‐generation EGFR‐TKIs (1st TKIs), or afatinib, a second‐generation EGFR‐TKI (2nd TKI), increases the incidence of ILD in patients who have received anti‐PD‐1/PD‐L1 antibody therapy immediately prior to TKIs. In addition, little is known about the incidence of ILD related to EGFR‐TKIs when they are administered immediately before anti‐PD‐1/PD‐L1 antibody therapy. We retrospectively examined the incidence of ILD associated with EGFR‐TKI treatment both immediately before and after nivolumab therapy.

Methods {#tca13039-sec-0002}
=======

Patient selection {#tca13039-sec-0003}
-----------------

We selected patients with cytologically or histologically proven advanced *EGFR* mutation‐positive NSCLC (stage III or IV, or recurrence after surgical resection) aged \> 20 years who received EGFR‐TKIs immediately before and/or after nivolumab or pembrolizumab treatment. Exclusion criteria were serious situations, such as concomitant serious illness, uncontrolled angina pectoris, heart failure, or uncontrolled diabetes mellitus. The institutional ethics committee of the Saitama Medical University International Medical Center approved this study.

Results {#tca13039-sec-0004}
=======

Patient demographics {#tca13039-sec-0005}
--------------------

Thirty‐one patients with advanced *EGFR* mutation‐positive NSCLC were treated with nivolumab at Saitama Medical University International Medical Center from January 2016 to August 2018. Five patients were excluded because they were not administered EGFR‐TKIs immediately before or after nivolumab treatment. A total of 26 patients (10 men, 16 women; median age 69 years, range: 44--80) were included in the analysis. Table [1](#tca13039-tbl-0001){ref-type="table"} shows the patient characteristics and the specific sequence of chemotherapeutic agents administered. Eight patients (31%) had a smoking history; 23 had stage IV disease, 1 had stage III; and 2 patients experienced recurrence after surgical resection. Nine (34.6%) patients had an Eastern Cooperative Oncology Group performance status (PS) of 0, six (23.1%) patients a PS of 1, eight (30.7%) patients a PS of 2, and three (11.5%) patients a PS of 3. All tumors had adenocarcinoma (AC) histology. *EGFR* mutation analysis showed that 14 (53.8%) patients had exon 19 deletions, 10 (38.5%) patients had L858R mutations (exon 21), and 2 (7.7%) had other mutations. Only two (7.7%) patients had a history of thoracic radiation therapy, and no patients had pre‐existing interstitial lung disease.

###### 

Patient demographics

                                                        EGFR‐TKI sequence just before or after ICI                                   
  --------- ---- --- ----- -------- --- ----- ----- --- -------------------------------------------- --------------- --------------- -----
  Case 1     53   F   No    L858R    0   IV    No   6   Afatinib                                     Nivolumab       Pemetrexed       No
  Case 2     57   M   Yes   Del 19   1   IV    No   6   Pemetrexed                                   Nivolumab       Osimertinib      Yes
  Case 3     57   F   No    Del 19   2   IV    No   3   Afatinib                                     Nivolumab       Osimertinib      No
  Case 4     76   M   Yes   Del 19   1   IV    No   6   Docetaxel                                    Nivolumab       Osimertinib      Yes
  Case 5     64   F   No    Del 19   0   IV    No   4   Gefitinib                                    Nivolumab       none             No
  Case 6     69   F   No    Del 19   2   IV    No   4   Afatinib                                     Nivolumab       none             No
  Case 7     75   M   Yes   Del 19   2   IV    No   6   Afatinib                                     Nivolumab       Osimertinib      No
  Case 8     79   F   No    L858R    1   IV    No   6   Afatinib                                     Nivolumab       none             Yes
  Case 9     70   F   Yes   L858R    2   IV    No   3   Afatinib                                     Nivolumab       none             No
  Case 10    62   F   No    Del 19   0   IV    No   3   Afatinib                                     Nivolumab       DTX/RAM          No
  Case 11    51   M   No    Del 19   3   IV    No   3   Erlotinib                                    Nivolumab       Osimertinib      No
  Case 12    71   F   No    L858R    0   IV    No   5   Osimertinib                                  Nivolumab       Erlotinib+Bev    No
  Case 13    80   M   No    L858R    0   IV    No   2   Pemetrexed                                   Nivolumab       Gefitinib        No
  Case 14    75   F   No    Del 19   0   IV    No   5   Osimertinib                                  Nivolumab       none             No
  Case 15    73   M   No    L858R    3   Rec   No   3   Erlotinib                                    Nivolumab       Osimertinib      Yes
  Case 16    44   M   No    Del 19   1   IV    Yes  7   Osimertinib                                  Nivolumab       Pemetrexed       No
  Case 17    59   M   Yes   L858R    1   III   No   3   Afatinib                                     Nivolumab       none             No
  Case 18    73   F   No    L858R    0   IV    No   5   Osimertinib                                  Nivolumab       DTX/RAM          No
  Case 19    48   F   Yes   Del 19   3   IV    Yes  7   Pemetrexed                                   Nivolumab       Afatinib         No
  Case 20    77   M   Yes   Del 19   2   IV    No   4   Erlotinib                                    Nivolumab       DTX/RAM          No
  Case 21    70   M   Yes   Del 19   2   IV    No   5   Pemetrexed                                   Nivolumab       Erlotinib+Bev    No
  Case 22    69   F   No    Del 19   0   IV    No   4   Erlotinib+Bev                                Nivolumab       none             No
  Case 23    67   F   No    L858R    1   IV    No   4   Osimertinib                                  Nivolumab       none             No
  Case 24    66   F   No    L858R    2   IV    No   5   Osimertinib                                  Pembrolizumab   Afatinib         No
  Case 25    79   F   No    Del 19   2   Rec   No   8   Erlotinib+ Bev                               Pembrolizumab   None             No
  Case 26    70   F   No    L858R    0   IV    No   4   Afatinib                                     Nivolumab       Osimertinib      No

Bev, bevacizumab; Del 19, exon 19 deletion; DTX, docetaxel; F, female; ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; L858R, exon 21 L858R; M, male; No. of pts., number of patients; PS, performance status; RAM, ramucirumab; Rec, recurrence after operation; TKI, tyrosine kinase inhibitor.

Occurrence of interstitial lung disease {#tca13039-sec-0006}
---------------------------------------

Four patients (15.3%) developed ILD during EGFR‐TKI therapy (cases 2, 4, 8, and 15). The detailed characteristics of these patients are presented in Table [2](#tca13039-tbl-0002){ref-type="table"}. Three of the four developed ILD during the administration of osimertinib after nivolumab therapy (cases 2, 4, and 15), and the remaining patient during afatinib before nivolumab (case 8). The radiological patterns of ILD were hypersensitive pneumonitis (HP) in one patient and cryptogenic organizing pneumonia (COP) in three patients (Table [2](#tca13039-tbl-0002){ref-type="table"}, Fig [1](#tca13039-fig-0001){ref-type="fig"}). All patients were treated with steroid therapy after discontinuation of EGFR‐TKI therapy, which resulted in ILD resolution in all.

###### 

ILD patient characteristics

  Factors                                                                                                                      Case 2           Case 4           Case 8          Case 15
  ----------------------------------------------------------------------------------------------------------------------- ---------------- ---------------- ---------------- ----------------
  Age (years)/Gender                                                                                                          57/Male          76/Male         79/Female         73/Male
  Interval between the final Niv and initiation of EGFR‐TKIs/interval between final EGFR‐TKIs and the initiation of Niv       20 days          5 months          2 days          15 days
  CTCAE grade of ILD                                                                                                             3                2                2                2
  ILD‐induced EGFR‐TKI                                                                                                      Osimertinib      Osimertinib        Afatinib       Osimertinib
  Interval from final EGFR‐TKI to onset of ILD                                                                                1 month          4 months         1 month          1 month
  Radiological pattern of ILD                                                                                                HP pattern      COP pattern      COP pattern      COP pattern
  Treatment for ILD                                                                                                        Corticosteroid   Corticosteroid   Corticosteroid   Corticosteroid
  Outcome of ILD                                                                                                              Recovery         Recovery         Recovery         Recovery

COP, cryptogenic organizing pneumonia; CTCAE, Common Terminology Criteria for Adverse Events; HP, hypersensitive pneumonitis; ILD, interstitial lung disease; Niv, nivolumab; TKI, tyrosine kinase inhibitor.

![Radiological patterns of interstitial lung disease show hypersensitive pneumonitis in one patient (case 2) and cryptogenic organizing pneumonia in three patients (cases 4, 8, and 15).](TCA-10-975-g001){#tca13039-fig-0001}

The frequency of ILD occurrence according to the chemotherapy sequence pattern of EGFR‐TKI and anti‐PD‐1 antibody administration was then analyzed. Patients were categorized into groups as follows: group 1 (cases 2, 4, 13, 19, and 21) were administered EGFR‐TKIs after anti‐PD‐1 antibodies; group 2 (cases 1, 5, 6, 8, 9,10, 14, 16, 17, 18, 20, 22, 23, and 25) were administered EGFR‐TKIs before anti‐PD‐1 antibodies; and group 3 (cases 3, 7, 11, 12, 15, 24, and 26) were administered EGFR‐TKIs both before and after anti‐PD‐1 antibodies. The five patients in group 1 were administered osimertinib (2), erlotinib (2), and gefitinib (1). The 14 patients in group 2 were administered afatinib (5), erlotinib (4), gefitinib (1), and osimertinib (3). In group 3, three patients were sequentially administered afatinib before nivolumab followed by osimertinib; two were administered erlotinib before nivolumab followed by osimertinib; and two patients were administered osimertinib before nivolumab followed by either erlotinib or afatinib. Twenty‐one patients were administered EGFR‐TKIs immediately before nivolumab: gefitinib (1), erlotinib (5), afatinib (9), and osimertinib (6). Of these 21 patients, ILD was observed in one patient (4.7%) who was administered afatinib. Twelve patients were treated with the EGFR‐TKIs immediately after nivolumab; gefitinib (1), erlotinib (2), afatinib (2), and osimertinib (7). Three (25%) of these patients experienced ILD; osimertinib was administered to all. ILD was not observed in the five patients who were treated with 1st or 2nd TKIs, but ILD was in observed in three of the seven patients (42.8%) administered osimertinib.

Discussion {#tca13039-sec-0007}
==========

This is the first study to investigate the incidence of ILD related to a third‐generation EGFR‐TKI administered immediately before and/or after nivolumab in patients with advanced *EGFR* mutation‐positive NSCLC. We found that 1st and 2nd TKIs were not associated with the development of ILD in the treatment sequence of nivolumab followed by EGFR‐TKIs, whereas osimertinib, a third‐generation TKI, was. Moreover, the administration of an EGFR‐TKI immediately before nivolumab therapy was not associated with the development of ILD, even if osimertinib was administered. Although it remains unclear why the synergistic effect differs between nivolumab and EGFR‐TKIs of different generations, we believe that 1st or 2nd TKIs should be used preferentially in regimens that prescribe EGFR‐TKIs immediately after nivolumab. We also confirmed that the administration of nivolumab is tolerable when immediately following any EGFR‐TKI, including osimertinib, without increasing toxicity.

In the present study, the development of ILD was observed in patients who underwent osimertinib immediately after nivolumab therapy, consistent with previous reports.[2](#tca13039-bib-0002){ref-type="ref"}, [3](#tca13039-bib-0003){ref-type="ref"}, [4](#tca13039-bib-0004){ref-type="ref"} Kotake *et al.* also reported that ILD was observed in four out of 19 (21%) patients administered osimertinib and three of these four patients were treated with osimertinib immediately after nivolumab.[2](#tca13039-bib-0002){ref-type="ref"} Although the detailed mechanism remains unknown, prior nivolumab treatment may increase the risk of osimertinib‐induced ILD. In a previous study, osimertinib‐induced ILD was observed in 7.3% of Japanese patients,[5](#tca13039-bib-0005){ref-type="ref"} differing from the 42.8% incidence in our study. A recent trial indicated that nivolumab as an anti‐PD‐1 antibody continues to bind to the PD‐1 on T cells for approximately two months.[6](#tca13039-bib-0006){ref-type="ref"} The synergistic effect of osimertinib and nivolumab may contribute to the high incidence of ILD. Recently, Kato *et al.* reported that nivolumab‐induced ILD was observed in 7.2% of patients, with radiological imaging showing a pattern of organized pneumonia or nonspecific interstitial pneumonia without traction bronchiectasis.[7](#tca13039-bib-0007){ref-type="ref"} The radiological findings of ILD in our study also revealed a pattern of organized pneumonia. However, our results suggest that the sequential administration of nivolumab followed by 1st or 2nd TKIs within a short interval was not linked to the development of ILD. We speculate that the mechanism of ILD development is different between 1st/2nd TKIs and osimertinib, and the activation of T‐cell effects by ICIs may upregulate this effect synergistically to cause ILD with osimertinib but not 1st or 2nd TKIs.

In conclusion, the administration of 1st or 2nd TKIs immediately after nivolumab did not increase the risk of the development of ILD, but ILD did occur when nivolumab was followed by osimertinib. Sequential therapy of any EGFR‐TKI immediately before nivolumab is acceptable without causing ILD. However, our analysis was retrospective with a limited sample size, which may bias the results of our study. Further investigation with a large‐scale prospective study is needed to confirm our results.
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